Karen Wonders, PhD, of Wright State University, discusses the safety and efficacy of exercise during cancer treatment in minimizing toxicities and addressing the short- and long-term effects of cancer therapy. Dr. Wonders suggests that exercise becomes a standard of care for patients with cancer (Abstract HSR20-110).
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) which has proved to be a promising method for patient self-management. Patient care sequence plans markedly improved several aspects of patient self-management, as well as delivery of multimodality care (Abstract BPI20-017).
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who received talazoparib vs physician’s choice of chemotherapy (Abstract CLO20-039).
Barbara DeVivo, PhD, MBA, of Westmont College, talks about how the culture and structure of tumor boards—and their invisible status hierarchies—may hamper collaboration and influence the way providers treat patients with cancer (Abstract BPI20-020).
Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those receiving chemotherapy) and used less supportive care medication (Abstract CLO20-052).
Elizabeth Reed, MD, of the University of Nebraska Medical Center Fred & Pamela Buffett Cancer Center, talks about how she and her team sought to help rural oncology providers recognize and address the physical, psychosocial, and decision-making needs of young women with breast cancer by implementing clinical pathways and treatment guidelines (Abstract BPI20-014).
